{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-145656","form_type":"8-K","ticker":"TECX","cik":"0001681087","company_name":"Tectonic Therapeutic, Inc.","filed_at":"2022-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.815362+00:00","generated_at":"2026-06-25T21:47:11.556197+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"AVROBIO Q1 net loss $29.8M, cash runway into Q1 2024; cystinosis trial fully enrolled","bullets":["Net loss $29.8M in Q1 2022, up from $26.9M in Q1 2021.","R&D expenses $19.3M; G&A $10.2M including severance costs.","Cash and equivalents $161.7M as of Mar 31, 2022; runway into Q1 2024.","Cystinosis Phase 1/2 trial fully enrolled (6 patients); new data at ASGCT.","Plan to start company-sponsored trials in 2023 for cystinosis, Gaucher type 3, Hunter, Pompe."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-145656","json":"https://secwatch.observer/filing/0001193125-22-145656.json","markdown":"https://secwatch.observer/filing/0001193125-22-145656.md","text":"https://secwatch.observer/filing/0001193125-22-145656.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1681087/000119312522145656/0001193125-22-145656-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1681087/000119312522145656/d356485d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T21:47:11.556197+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}